Based on the key indicators related to Milestone Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Milestone Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At this time, Milestone Pharmaceuticals' Total Current Assets are comparatively stable compared to the past year. Accumulated Other Comprehensive Income is likely to gain to about 58.5 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 18.3 M in 2025. Key indicators impacting Milestone Pharmaceuticals' financial strength include:
The financial analysis of Milestone Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Milestone Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the imprecision that can be found in Milestone Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Milestone Pharmaceuticals. Check Milestone Pharmaceuticals' Beneish M Score to see the likelihood of Milestone Pharmaceuticals' management manipulating its earnings.
Milestone Pharmaceuticals Stock Summary
Milestone Pharmaceuticals competes with DiaMedica Therapeutics, Seres Therapeutics, Inhibikase Therapeutics, Oncolytics Biotech, and Scpharmaceuticals. Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Milestone Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Milestone Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Milestone Pharmaceuticals competition to find correlations between indicators driving Milestone Pharmaceuticals's intrinsic value. More Info.
Milestone Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Milestone Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Milestone Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Milestone Pharmaceuticals Systematic Risk
Milestone Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Milestone Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on Milestone Pharmaceuticals correlated with the market. If Beta is less than 0 Milestone Pharmaceuticals generally moves in the opposite direction as compared to the market. If Milestone Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Milestone Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Milestone Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Milestone Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Milestone Pharmaceuticals Thematic Clasifications
Milestone Pharmaceuticals is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Milestone Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Milestone Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Milestone Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.44)
At this time, Milestone Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Milestone Pharmaceuticals January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Milestone Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Milestone Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Milestone Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Milestone Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Milestone Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.